How many units of CagriSema should I draw?

It depends on your vial size, BAC water, and dose. For a 3mg vial with 0mL BAC water, a beginner dose of 0.5mg is typically 0 units on a U-100 syringe. Use the calculator above for your exact numbers.

How much BAC water should I add to CagriSema?

The standard amount is 0mL of bacteriostatic water for a 3mg vial. More water gives a more dilute solution — easier to measure small doses. Less water means fewer injections per vial. Adjust the BAC water slider in the calculator to see how it changes your syringe units.

How long does a CagriSema vial last?

At a beginner dose of 0.5mg weekly, a 3mg vial lasts about 6000 doses. The calculator shows exact doses per vial for your selected tier.

What syringe should I use for CagriSema?

Most people use a U-100 insulin syringe (1mL / 100 units). For very small doses, a U-50 or U-30 syringe gives better precision. The calculator adjusts units automatically for whichever syringe you pick.

CagriSema Dosage Calculator

Weight LossInjectionPhase 3~7 days half-life

CagriSema is a first-in-class, fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist) developed by Novo Nordisk.

Average 22.7% body weight loss over 68 weeks (REDEFINE 1, treatment-policy estimate 20.4%)Dual mechanism: amylin + GLP-1 targets two separate satiety pathwaysSuperior weight loss compared to semaglutide alone (22.7% vs 16.1%)Approximately 40% of patients achieved 25% or more weight loss

Vial Size

BAC Water (mL)

Dosing Level

0.5mcg · Weekly

Custom Dose (mcg) — optional

Syringe Type

0.0 units

100 units (1mL)

Concentration

mcg/mL

Draw Volume

< 0.001

Syringe Units

< 0.1

units

Doses / Vial

doses

Summary: Add 0mL BAC water to your 3mg vial. Draw to < 0.1 units on a U-100 syringe for a 0.5mcg dose. This vial will last 0 doses.

Cycle Planner

Cycle Length (weeks)

Price Per Vial ($) — optional

Subcutaneous. Typical beginner frequency: weekly.

CagriSema Pharmacokinetics

Pharmacokinetics — Active Dose Over Time

t½ = ~7 days (semaglutide component ~158h; cagrilintide component ~184h)

After 1 half-life (7d): 50% remainsAfter 2 half-lives (14d): 25% remainsAfter 3 half-lives (21d): 12.5% remains

At a 1.7mcg dose: 50% = 1mcg remaining after 7d. Recommended frequency: Weekly.

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.

CagriSema Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	0.5mg	Weekly
Moderate	1.7mg	Weekly
Aggressive	2.4mg	Weekly

Note: Fixed-ratio combination of cagrilintide 2.4 mg + semaglutide 2.4 mg in a single pre-filled pen. Titrate over 16 weeks: 0.25 mg each (wk 1-4), 0.5 mg (wk 5-8), 1.0 mg (wk 9-12), 1.7 mg (wk 13-16), then 2.4 mg maintenance. Not yet FDA-approved — Phase 3 REDEFINE program ongoing. NDA submitted to FDA.

About CagriSema

CagriSema is a first-in-class, fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist) developed by Novo Nordisk. By targeting two distinct appetite-regulating pathways — amylin and GLP-1 — in a single weekly injection, CagriSema produces greater weight loss than either component alone. In the Phase 3 REDEFINE 1 trial, participants without diabetes lost an average of 22.7% of their body weight over 68 weeks, with roughly 40% achieving at least 25% weight loss. REDEFINE 2 demonstrated 15.7% weight loss in adults with type 2 diabetes. Novo Nordisk has submitted an NDA to the FDA, positioning CagriSema as the next generation of obesity treatment.

View full CagriSemaguide →Add to schedule →